The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study

So-Youn Jung, Junsoo Jeong, Seung-Ho Shin, Youngmee Kwon, Eun-A Kim, Kyong Lan Ko, Kyung Hwan Shin, Keun Seok Lee, In Hae Park, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Jungsil Ro*

Abstract

Background: Although the invasive lobular carcinoma (ILC) is the second most frequent histologic subtype in Western countries, its incidence is much lower in Asia, and its characteristics are less well known.

Methods: We assessed the clinical characteristics and outcomes of 83 Korean patients (2.8%) with ILC for comparison with 2,833 (97.2%) with the invasive ductal carcinoma (IDC), including 1,088 (37.3%) with the luminal A subtype (LA-IDC).

Results: The mean age of all patients was 48.2 years, with no significant differences among the groups. Compared to IDC, ILC showed a larger tumor size (≥T2, 59.8% vs. 38.8%, \( P = 0.001 \)), a lower histologic grade (HG 1/2, 90.4% vs. 64.4%, \( P < 0.001 \)), more frequent estrogen receptor positive (90.4% vs. 64.4%, \( P < 0.001 \)), progesterone receptor positive (71.1% vs. 50.1%, \( P < 0.001 \)) and HER2 negative (97.5% vs. 74.6%, \( P < 0.001 \)) status, and lower Ki-67 expression (10.3% ± 10.6% vs. 20.6% ± 19.8%, \( P < 0.001 \)), as well as being more likely to be of the luminal A subtype (91.4% vs. 51.2%, \( P < 0.001 \)). Six (7.2%) ILC and 359 (12.7%) IDC patients developed disease recurrence, with a median follow-up of 56.4 (range 4.9-136.6) months. The outcome of ILC was close to LA-IDC (HR 0.77 for recurrence, 95% CI 0.31-1.90, \( P = 0.57 \); HR 0.75 for death, 95% CI 0.18-3.09, \( P = 0.70 \)) and significantly better than for the non-LA-IDC (HR 1.69 for recurrence, 95% CI 1.23-2.33, \( P = 0.001 \); HR 1.50 for death, 95% CI 0.97-2.33, \( P = 0.07 \)).

Conclusions: ILC, a rare histologic type of breast cancer in Korea, has distinctive clinicopathological characteristics similar to those of LA-IDC.

Background

The invasive lobular carcinoma (ILC), known to be the second most common histologic subtype of invasive breast cancer following the invasive ductal carcinoma (IDC), constitutes 8-14% of all breast cancers in most Western reports [1-3]. However, in Asia it appears to be very low, accounting for only 2-4% in Korea [4-6] and 1-4% in Japan [7,8].

Previous studies have demonstrated distinctive clinical and biologic characteristics for ILC as compared with IDC. For example, it is more likely to occur in older patients, be larger in size, be estrogen receptor (ER) and progesterone receptor (PgR) positive and have low to absent human epidermal growth factor receptor-2 (HER2) expression [9,10]. Traditionally, both ILC and IDC subtypes have received the same treatment, depending on their clinicopathological characteristics, and the prognosis is reported to be similar [10,11].

Recently, classification of breast cancers by gene expression profiling into particular subtypes has become established [12]. However, in clinical practice, the combination of expression of hormone receptors and HER2 by immunohistochemistry (IHC) is more commonly used to define breast cancers into the luminal A (ER+ or PgR+, HER2-), luminal B (ER+ or PgR+, HER2+), HER2-overexpressing (ER- and PgR-, HER2+), and triple-negative (TNBC: ER-, PgR-, HER2-) subtypes, which demonstrate major differences in clinical outcomes, with the luminal A subtype showing the best prognosis [13,14]. The relative distributions of these four immunohistochemically defined subtypes in the lobular lesions have yet to be established in detail.

The purpose of the current study was to analyze the characteristics of an ILC series and compare the clinical
and prognostic parameters with those of general IDC and of the luminal A subtype of IDC (LA-IDC).

Methods
Patients
All patients were treated at the National Cancer Center, Korea during the years from 2001 to 2008. A total of 83 consecutive cases diagnosed with pure ILC, including two cases with synchronous bilateral ILC, were enrolled in the study. All ILC cases were classic subtype except for one case which was pleomorphic type. This particular case was triple negative by IHC. To compare clinicopathological characteristics and prognoses, 2,833 consecutive patients diagnosed with IDC during the same period were also selected.

Clinicopathological evaluation
We retrospectively evaluated conventional clinicopathological factors, including treatment modalities (type of operation, use of chemotherapy, hormone therapy, anti-HER2 therapy and radiotherapy) and the IHC results for five biological factors (ER [SP1], Ventana; PgR [E2], Ventana; HER2 [polyclonal], DAKO; p53 [Bp53-11], Ventana; and Ki-67 [MIB-1], DAKO) using paraffin-embedded tissues according to the reported recommendations for tumor marker prognostic studies (REMARK) [15]. The pathological tumor stage was assessed according to the criteria described in the 6th edition of the American Joint Committee on Cancer (AJCC) staging manual [16]. The tumor grade was determined according to the Scarff-Bloom-Richardson classification modified by Elston and Ellis [17].

A cut-off value of 10% of positively stained nuclei was used to define ER and PgR positivity; HER2 was scored as 0-3+ by a pathologist (Y. Kwon) according to the method recommended for the Dako Hercep Test. Cases with IHC scores of 3+ or 2+ with gene amplification by fluorescence in situ hybridization (FISH) were considered positive for HER2. Cells with positive staining for Ki-67 and p53 were counted and expressed as a percentage. For p53, we scored the lesions as 0-3+ (0, negative; 1+, ≤25%; 2+, 25-50%; 3+, >50%). For the prognosis comparison, low expression was defined as Ki-67 < 20% and p53 ≤ 25% (median values for all evaluated tumors).

For the subgroup analysis, the definition of Luminal A was as follows: positive ER or PgR by IHC, negative HER2 represented by an IHC score of 0 or 1+, or 2+ if not amplified by FISH. The HER2 cases of an IHC score of 2+ but no FISH results were counted as unknowns. The definitions of the other subtypes were as follows: Luminal B, ER or PgR positive and HER2 positive; HER2 overexpressing, low ER and PgR scores but HER2 positive; TNBC, low ER and PgR scores and HER2-negative.

Treatment, including surgery, adjuvant chemo, endocrine or anti-HER2 therapy, and radiotherapy, was applied equally to patients with ILC and IDC, dependent on the clinicopathological characteristics.

Statistical analysis
The primary endpoints of this study were disease-free survival (DFS) and overall survival (OS). The DFS period was defined as the interval from the date of diagnosis to the date of the first observation of disease recurrence, either loco-regional recurrence or distant metastasis, or the last follow-up date without any evidence of recurrence. Overall survival was calculated from the date of primary breast cancer diagnosis to the date of death or last follow-up.

To compare the clinicopathological characteristics between pairs of groups, we used the Student’s t-test and the chi-square test. The DFS and OS rates were calculated using the Kaplan-Meier method, and the groups were compared using the log-rank test. For the multivariate analysis, Cox regression analysis was applied. Statistical analyses were performed using Stata 10.0 for Windows (Stata Corporation Station, TX, USA).

This study protocol was reviewed and approved by the Institutional Review Board of the National Cancer Center (NCCNCS-10-371), Korea, and it complied with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects. The ethical review board supported that informed consent was not required for this study.

Results
Patient characteristics
The clinicopathological characteristics of the 83 ILC patients and 2,833 IDC patients are summarized in Table 1. The mean ages were 48.3 years and 48.2 years, respectively, with no difference in the distributions of age at diagnosis between ILC and IDC (Figure 1). Two patients with mixed lobular and ductal cancers were excluded from the analysis.

Compared to the IDC group, significantly more ILC patients presented with a low histologic grade (HG) (HG1 or 2, 90.4% vs. 54.9%, P < 0.001) and a large tumor size (≥T2, 59.8% vs. 38.8%, P = 0.001), although no difference was noted with respect to nodal involvement (43.9% vs. 41.3%, P = 0.18).

Significantly more tumors were positive for hormone receptors and had a negative HER2 status in the ILC group as compared to the IDC group (ER+, 90.4% vs. 64.4%, P < 0.001; PgR+, 71.1% vs. 50.1%, P < 0.001; HER2-, 97.5% vs. 74.6%, P < 0.001), with a greater proportion of the luminal A subtype in the ILC group (91.4% vs. 51.2%, P < 0.001). In addition, the mean Ki-67 value was lower in
| Characteristic          | ILC (N = 83) | IDC (N = 2833) | P     | LA-IDC (N = 1088) | P     |
|------------------------|--------------|----------------|-------|-------------------|-------|
| Mean age (years)       | 48.3 ± 8.5   | 48.2 ± 10.5    | 0.93  | 47.9 ± 10.2       | 0.71  |
| pT                     |              |                |       |                   |       |
| T1                     | 33           | 40.2           | 0.001 | 667               | 61.4  |
| T2                     | 45           | 54.9           | 0.349 | 373               | 34.4  |
| T3                     | 4            | 4.9            | 0.31  | 37                | 3.4   |
| T4                     | 0            | 0              | 0.8   | 9                 | 0.8   |
| Tumor stage            |              |                |       |                   |       |
| Stage                  |              |                |       |                   |       |
| I                      | 25           | 30.1           | 0.06  | 426               | 39.3  |
| II                     | 44           | 53             | 0.44  | 476               | 44    |
| III                    | 14           | 16.9           | 0.19  | 157               | 14.5  |
| IV                     | 0            | 0              | 0.2   | 24                | 2.2   |
| Unknown                | 1            | 39             | 0.91  | 19                |       |
| M                      |              |                |       |                   |       |
| M0                     | 83           | 100            | 0.19  | 1064              | 97.8  |
| M1                     | 0            | 0              |       | 24                | 2.2   |
| Stage                  |              |                |       |                   |       |
| HG                     |              |                |       |                   |       |
| 1 or 2                 | 75           | 90.4           | <0.001| 576               | 57.3  |
| 3                      | 8            | 9.6            | 0.42  | 429               | 42.7  |
| HER2                   |              |                |       |                   |       |
| Positive               | 75           | 90.4           | <0.001| 212               |       |
| Negative               | 8            | 9.6            | 0.36  | 8                 |       |
| HER2                   |              |                |       |                   |       |
| Positive               | 59           | 71.1           | <0.001| 1420              |       |
| Negative               | 24           | 28.9           | 0.49  | 1413              |       |
| HER2                   |              |                |       |                   |       |
| Positive               | 79           | 97.5           | <0.001| 1586              |       |
| Negative               | 2            | 2.5            | 0.25  | 540               |       |
| Subtype                |              |                |       |                   |       |
| Luminal A              | 74           | 91.4           | <0.001| 1088              |       |
| Non-LA                 | 7            | 8.6            | 0.48  | 1038              |       |
| p53                    |              |                |       |                   |       |
| 0 or 1+                | 74           | 93.7           | <0.001| 2146              |       |
| 2+ or 3+               | 5            | 6.3            | 0.23  | 616               |       |
| Unknown                | 4            | 71             | 0.28  | 70                |       |
| Ki-67                  |              |                |       |                   |       |
| Operation              |              |                |       |                   |       |
| BCS                    | 57           | 68.7           | 0.18  | 786               | 73    |
| Mastectomy             | 26           | 31.3           | 0.39  | 290               | 27    |
| None                   | 0            | 0              |       | 26                | 3     |
| Adjuvant therapy       |              |                |       |                   |       |
| Chemotherapy           | Yes          | 68             | 81.9  | 922               | 84.7  |
|                       | No           | 15             | 18.1  | 450               | 15.9  |
| Hormone therapy        | Yes          | 79             | 95.2  | 2113              | 74.6  |
|                       | No           | 4              | 4.8   | 720               | 25.4  |
| Anti-HER2 therapy      | Yes†         | 1              | 1.2   | 164               | 5.8   |
|                       | No           | 82             | 98.8  | 2669              | 94.2  |
| Radiotherapy           | Yes          | 64             | 77.1  | 879               | 808   |
|                       | No           | 19             | 22.9  | 510               | 18    |

* Including 2+ for HER2 by immunohistochemistry without FISH.
† Thirty-seven of these patients were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial [25] and 53 patients were enrolled in the Tykerb Evaluation After Chemotherapy (TEACH) trial [26].

BCS, breast-conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological nodal stage; PgR, progesterone receptor.
the ILC group compared to the IDC group (10.3 ± 10.6% vs. 20.6 ± 19.8%, P < 0.001).

Because 91.4% of ILC were of the luminal A subtype, we further compared ILC to the 1,088 LA-IDC. Whereas significant differences between ILC and LA-IDC were found for size, HG and Ki-67, the rates of nodal involvement and the expression of p53 were similar (Table 1).

The treatment modalities in the ILC group were also comparable to those used in the LA-IDC group. One of two patients with a HER2 positive tumor among the ILC group who developed disease recurrence received anti-HER2 treatment upon recurrence.

Univariate analysis of DFS and OS of ILC compared to IDC patients
During the median follow-up of 56.4 (range 4.9-136.6) months, 365 patients experienced disease recurrence (6/83 ILC vs. 359/2833 IDC, P = 0.18) and 213 patients died (3/83 ILC vs. 210/2833 IDC, P = 0.28). One ILC patient experienced local recurrence, one contralateral breast cancer, and four distant metastasis.

Table 2 shows the results of the univariate analysis of DFS and OS of the ILC group and of all IDC patients. Significant prognostic factors for DFS were age at diagnosis; tumor size; lymph node involvement; individual ER, PgR, and HER2 statuses; p53 (0 or 1+ vs. 2+ or 3+); Ki-67 (cut-off: 20%); the type of operation (breast conserving surgery [BCS] vs. mastectomy); adjuvant hormone therapy; and intrinsic subtype (luminal A vs. non-luminal A). However, there was no significant difference in the 5-year DFS rate between ILC and all IDC (91.7% in ILC vs. 87.4% in IDC, P = 0.31).

In the univariate analysis of OS, age, tumor size, nodal status, distant metastasis at diagnosis, individual ER, PgR, and HER2 statuses, p53, Ki-67, the type of operation, adjuvant hormone therapy and intrinsic subtype were prognostic factors. The 5-year OS rate was 93.6% for the ILC group and 92.5% for the IDC group (P = 0.38).

In this study, we classified the total 2,916 patients into ILC and four subtypes of IDC and compared the clinical outcomes. Figure 2 (a, b) presents the DFS and OS curves. The prognosis of ILC was similar to that of LA-IDC and was more favorable than with other subtypes of IDC; the 5-year DFS rates being 91.7% vs. 89.1% for LA-IDC, 80.7% for the luminal B subtype of IDC (LB-IDC), 78.9% for the triple-negative subtype of IDC (TN-IDC), and 75.9% for the HER2 overexpressing subtype (P < 0.001). The 5-year OS rates were 93.6%, vs. 93.4%, 92.8%, 85.8%, and 83.9%, respectively (P < 0.001).

Multivariate analysis of DFS and OS of ILC compared to IDC, LA-IDC, and non-LA-IDC
Using the significant variables determined by the univariate analysis, we performed a multivariate analysis for DFS and OS (Table 3). Patients younger than 35 years (HR 2.17. 95% CI 1.55-3.02, P < 0.001), with a larger tumor size (HR 1.85, 95% CI 1.44-2.37, P < 0.001), and lymph node involvement (HR 2.81, 95% CI 2.15-3.68, P < 0.001) demonstrated an unfavorable prognosis (Table 3). Non-LA-IDC (LB-IDC, TN-IDC, and HER2-overexpressing subtypes) showed a more unfavorable prognosis compared to LA-IDC (HR 1.69, 95% CI 1.23-2.33, P = 0.001), but the DFS rates for ILC and LA-IDC were similar (HR 0.77, 95% CI 0.31-1.90, P = 0.57).

For OS, a young age (HR 1.96. 95% CI 1.27-3.02, P = 0.002), larger tumor size (HR 1.72, 95% CI 1.24-2.40, P = 0.001), lymph node involvement (HR 2.61, 95% CI 1.84-3.69, P < 0.001), the presence of distant metastasis at first diagnosis (HR 10.75, 95% CI 6.29-18.37, P < 0.001), p53 overexpression (HR 1.64, 95% CI 1.17-2.31, P = 0.004), and no hormone therapy (HR 1.81, 95% CI 1.21-2.71, P = 0.004) were identified as independent factors that were significantly associated with mortality (Table 3). However, OS did not differ between ILC and LA-IDC patients (ILC; HR 0.75, 95% CI 0.31-1.90, P = 0.70).

Figure 2 (c, d) shows the DFS and OS curves adjusted for other prognostic factors for ILC and IDC subtypes. The DFS curves for ILC were similar to those for LA-IDC and were more favorable than those for non-LA-IDC (P = 0.03). The OS of ILC and LA-IDC was better than that of non-LA-IDC, but the difference did not reach statistical significance (P = 0.16).

Discussion
ILC constitutes 2-4% of all breast cancer in Korea, as presented in the current study, which is much lower...
Table 2 Univariate analysis of disease-free survival (DFS) and overall survival (OS) of all patients

| Characteristic                      | Patients (n) | 5-yr DFS rate (%) | P    | 5-yr OS rate (%) | P    |
|-------------------------------------|--------------|-------------------|------|------------------|------|
| Age                                 |              |                   |      |                  |      |
| <35 yrs                             | 226          | 79.3              | <0.001 | 86.3             | <0.001 |
| ≥35 yrs                             | 2690         | 88.2              |       | 93.1             |       |
| pT                                  |              |                   |      |                  |      |
| T1                                  | 1763         | 91.9              | <0.001 | 95.1             | <0.001 |
| ≥T2                                 | 1147         | 81                |       | 89.2             |       |
| Unknown                             | 6            |                   |       |                  |       |
| pN                                  |              |                   |      |                  |      |
| Negative                            | 1685         | 93.8              | <0.001 | 95.9             | <0.001 |
| Positive                            | 1191         | 81.4              |       | 89.6             |       |
| Unknown                             | 40           |                   |       |                  |       |
| M                                   |              |                   |      |                  |      |
| 0                                   | 2860         |                   | 93.9 | <0.001           |       |
| 1                                   | 56           |                   | 24.6 |                   |       |
| Stage                               |              |                   |      |                  |      |
| I                                   | 1209         | 95.2              | <0.001 | 97.2             | <0.001 |
| II                                  | 1292         | 89.4              |       | 94.8             |       |
| III                                 | 351          | 69.2              |       | 80.4             |       |
| IV                                  | 56           |                   | 24.6 |                   |       |
| Unknown                             | 8            |                   |       |                  |       |
| HG                                  |              |                   |      |                  |      |
| 1 or 2                              | 1513         | 88.7              | 0.39 | 93               | 0.84 |
| 3                                   | 1191         | 86.8              |       | 92.7             |       |
| Unknown                             | 212          |                   |       |                  |       |
| ER                                  |              |                   |      |                  |      |
| Positive                            | 1900         | 91.1              | <0.001 | 95.7             | <0.001 |
| Negative                            | 1016         | 80.6              |       | 86.8             |       |
| PgR                                 |              |                   |      |                  |      |
| Positive                            | 1479         | 92.4              | <0.001 | 96.6             | <0.001 |
| Negative                            | 1437         | 82.7              |       | 88.7             |       |
| HER2                                |              |                   |      |                  |      |
| Negative                            | 1665         | 86.1              | <0.001 | 91.4             | 0.001 |
| Positive                            | 542          | 78.4              |       | 88.3             |       |
| Unknown*                            | 709          |                   |       |                  |       |
| Subtype                             |              |                   |      |                  |      |
| Luminal A (LA)                      | 1162         | 89.3              | <0.001 | 93.9             | <0.001 |
| Non-LA                              | 1045         | 78.5              |       | 87.1             |       |
| Unknown                             | 709          |                   |       |                  |       |
| Histological type                   |              |                   |      |                  |      |
| ILC                                 | 83           | 91.7              | 0.31 | 93.6             | 0.38 |
| IDC                                 | 2833         | 87.4              |       | 92.5             |       |
| pS3                                 |              |                   |      |                  |      |
| 0 or 1+                             | 2220         | 90.9              | <0.001 | 95.2             | <0.001 |
| 2+ or 3+                            | 621          | 81.8              |       | 87.1             |       |
| Unknown                             | 65           |                   |       |                  |       |
| Ki-67                               |              |                   |      |                  |      |
| ≤20%                                | 1902         | 90.1              | <0.001 | 94.4             | <0.001 |
| >20%                                | 700          | 83.4              |       | 89.1             |       |
| Unknown                             | 314          |                   |       |                  |       |
| Operation                           |              |                   |      |                  |      |
| BCS                                 | 2166         | 89.5              | <0.001 | 94.6             | <0.001 |
| Mastectomy                          | 724          | 84.2              |       | 88.6             |       |
| None                                | 27           |                   |       |                  |       |
| Adjuvant therapy                    |              |                   |      |                  |      |
| Chemotherapy                        |              |                   |      |                  |      |
| Yes                                 | 2318         | 87.7              | 0.38 | 92.6             | 0.87 |
| No                                  | 556          | 86.6              |       | 92.5             |       |
| Hormone therapy                     |              |                   |      |                  |      |
| Yes                                 | 2192         | 90.4              | <0.001 | 95.6             | <0.001 |
| No                                  | 724          | 78.9              |       | 83.9             |       |
| Anti-HER2 therapy                   |              |                   |      |                  |      |
| Yes in HER2-positive†               | 147          | 80.7              | 0.77 | 93.1             | 0.48 |
| No in HER2-positive                 | 395          | 77.4              |       | 86.9             |       |
| HER2-negative or unknown§           | 2374         |                   |       |                  |       |
| Radiotherapy                        |              |                   |      |                  |      |
| Yes                                 | 2387         | 87.8              | 0.4  | 92.3             | 0.38 |
| No                                  | 529          | 86.3              |       | 92.9             |       |

* Including 2+ for HER2 by immunohistochemistry without FISH.
† Thirty-seven of these patients were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial [25] and 53 patients were enrolled in the Tykerb Evaluation After Chemotherapy (TEACH) trial [26].
§ No anti-HER2 therapy due to negative or unknown for HER2 by immunohistochemistry without FISH.

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological nodal stage; PgR, progesterone receptor.
than the rate observed in most Western reports [1-3]. Although ILC occurs more often in older women in Western countries [9,10], our series demonstrated that age distributions were the same as those for overall IDC at diagnosis. Notably, the peak age of breast cancer patients in Korea is the late 40s, which is 10 to 20 years younger than that in Western countries [4]. In the present study, the tumor size of ILC was larger than that of IDC, as observed in other studies [10,18,19]. Detection may be delayed because ILC is often clinically

Table 3 Multivariate analysis of disease-free survival (DFS) and overall survival (OS)

|                | DFS          |          | OS           |          |
|----------------|--------------|----------|--------------|----------|
|                | HR 95% CI    | P        | HR 95% CI    | P        |
| Age (<35 yrs)  | 2.17 (1.55-3.02) | <0.001  | 1.96 (1.27-3.02) | 0.002    |
| pT (≥T2)       | 1.85 (1.44-2.37) | <0.001  | 1.72 (1.24-2.40) | 0.001    |
| pN (positive)  | 2.81 (2.15-3.68) | <0.001  | 2.61 (1.84-3.69) | <0.001   |
| M (1)          | -            | -        | 10.75 (6.29-18.37) | <0.001   |
| Subtype        |              |          |              |          |
| LA-IDC         | 1 (ref)      |          | 1 (ref)      |          |
| non LA-IDC     | 1.69 (1.23-2.33) | 0.001  | 1.5 (0.97-2.33) | 0.07     |
| ILC            | 0.77 (0.31-1.90) | 0.57    | 0.75 (0.18-3.09) | 0.7      |
| p53 (>25%)     | 1.27 (0.96-1.66) | 0.09    | 1.64 (1.17-2.31) | 0.004    |
| Ki-67 (≥20%)   | 1.06 (0.81-1.39) | 0.67    | 1.08 (0.77-1.50) | 0.67     |
| Operation (mastectomy) | 1.15 (0.89-1.48) | 0.29    | 1.14 (0.82-1.59) | 0.44     |
| Hormone therapy (no) | 1.19 (0.88-1.62) | 0.25    | 1.81 (1.21-2.71) | 0.004    |

CI, confidence interval; HG, histologic grade; HR, hazard ratio; LA, luminal A; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological nodal stage
impalpable or mammographically invisible due to a lack of desmoplasia in the stroma [20]. Despite the larger tumor size, the rate of lymph node involvement in ILC did not differ from that in general IDC, which may reflect the slow growth rate of ILC, and this finding is consistent with other reports [10,18]. Due to the difficulty associated with early detection, the larger tumor size in ILC adversely affected the outcomes of patients with poor DFS in the present study. We reported that ILC had lower histologic grade than IDC. Previously, Li et al. analyzed Surveillance, Epidemiology, and End Results Program data and demonstrated that ILC showed lower tumor grade than IDC specifically in 30-49 years old patient group [21]. Although Rakha et al. reported that histologic grade of ILC provided a strong predictor of outcome in breast cancer patients and should be provided routinely in pathology reports, we did not find such correlation [22].

One of the objectives of the present study was to characterize more comprehensively the biological phenotype of ILC. As previously reported [6,10], the majority of ILC showed ER or PgR positivity and HER2 negativity, which we defined as consistent with the LA-IDC subtype. Weigelt et al. also showed that most ILC fall into luminal A molecular subtype, although some ILC had cluster with either HER2 subtype or apocrine subtype [23]. Furthermore, ILC demonstrated lower p53 and Ki-67 expression compared to IDC and LA-IDC. All of these characteristics suggest that ILC likely originates from more differentiated luminal cells [24].

Previous studies have reported that the prognosis of ILC patients is similar to that of IDC patients [6,10,18], as confirmed in the present study. Arpino et al. analyzed 4,140 ILC patients and 45,169 not otherwise specified IDC patients and reported that the histologic type did not affect the prognosis despite the favorable biological phenotype of ILC [10]. However, the outcome of ILC in the present study was comparable to that of LA-IDC and significantly better than the outcomes of other, non-LA-IDC subtypes, when we further analyzed the prognosis by breast cancer subtype.

This study demonstrated a new aspect of ILC after constraining the data including biologic markers other than general tumor characteristics in the consecutive breast cancer patients who received consistent therapeutic approaches at a single center. Similar clinicopathological characteristics and clinical outcomes between ILC and LA-IDC were discovered after we further compared ILC with the four subtypes. To our knowledge, this is the first report to show such similarities between ILC and LA-IDC.

Conclusions
ILC has distinct clinicopathological characteristics with a larger tumor at presentation, a lower HG, ER/PgR positive and HER2 negative status, and low Ki-67 expression, as compared to overall IDC. This study shows that most ILC are luminal A breast cancer, the prognosis of ILC is similar to that of LA-IDC, and both are better than the other subtypes.

Abbreviations
CI: confidence interval; DFS: disease-free survival; ER: estrogen receptor; FISH: fluorescence in situ hybridization; HER2: human epidermal growth factor receptor-2; HR: hazard ratio; IDC: invasive ductal carcinoma; IHC: immunohistochemistry; ILC: invasive lobular carcinoma; LA: luminal A; OS: overall survival; PgR: progesterone receptor; TNBC: triple negative breast cancer

Acknowledgements
This study was supported in part by NCC grant 0910320.

Authors' contributions
SYJ participated in study design, data analysis and interpretation, manuscript drafting and revision. JJ participated in data acquisition. SHS participated in data acquisition. YK participated in data acquisition and manuscript revision. EAK participated in data acquisition and manuscript revision. KAS participated in data acquisition and manuscript revision. KLK participated in data acquisition and manuscript revision. KSL participated in data acquisition and manuscript revision. SL participated in data acquisition and manuscript revision. SWK participated in data acquisition and manuscript revision. HSK participated in data acquisition and manuscript revision. JR participated in study design, data analysis and interpretation, manuscript drafting and revision, and study supervision. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

References
1. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE: Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000, 88(11):2561-2569.
2. Singletary SE, Patel-Parekh L, Bland KI: Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg Oncol 2005, 24(2):289-299.
3. Vo TN, Meric-Bernstein F, Yi M, Buchholz TA, Ames FC, Kueerer HM, Bedrosian I, Hunt KK: Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 2006, 192(4):552-555.
4. Ko SS: Clinicopathological changes of biological characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 2008, 98(5):318-323.
5. Jeong J, Society TKBC: Nationwide Korean Breast Cancer Data of 2004 Using Breast Cancer Registration Program. Journal of breast cancer 2006, 9:151-161.
6. Lee JH, Park S, Park HS, Park BW: Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol 2010, 8(1):34.
7. Ohta T, Tsujimoto F, Nakajima Y: Ultrasonographic findings of invasive lobular carcinoma differentiation of invasive lobular carcinoma from invasive ductal carcinoma by ultrasonography. Breast cancer 2005, 128:7.
8. Fu L, Tsujiya S, Matsuyama I: Clinicopathologic features and incidence of invasive lobular carcinoma in Japanese women. Pathol Int 1999, 48:7.
9. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Therasi RL, Valero V, Budzard AL, Kuerer H, Buchholz TA, et al: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005, 23(1):41-48.
10. Arpino G, Bardou VJ, Clark GM, Elledge RM: Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004, 6(3):R149-156.
11. Silverstein MJ, Lewinsky BS, Waism L, Gerson ED, Colburn WI, Senofsky GM, Gamagami P. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994, 73(6):1673-1677.

12. Sorlie T, Tibshirani R, Parker J, Hastie T, Mamon J, Nobel A, Deng S, Johnson H, Peisahl R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423.

13. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.

14. Nam BH, Kim SY, Hs H, Kwon Y, Lee KS, Kim TH, Ro J. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008, 10(1):R20.

15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23(36):9067-9072.

16. Greene F, Page D, Fleming I. AJCC cancer staging manual. 6 edition. New York. Springer; 2002.

17. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991, 68(10):2142-2149.

18. Pestalozzi BC, Zahrchod D, Maillou E, Gusterson BA, Price KN, Gelber RD, Holmberg SL, Lindner J, Snyder R, Thurlimann B, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008, 26(18):3006-3014.

19. Satre-Garau X, Joume M, Asselain B, Vincent-Salomon A, Bruezboc P, Dornal T, Durand JC, Fourquet A, Pouillart P. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996, 77(1):113-120.

20. Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KJ, Winchester DP. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg 1998, 186(4):416-422.

21. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005, 93(9):1046-1052.

22. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 2008, 111(1):121-127.

23. Weigelt B, Horslings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MI, Van't Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008, 216(2):141-150.

24. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med 2009, 15(8):842-844.

25. Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008, 8(12):1883-1890.

26. Moy B, Goss PE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 2007, 76(4):499-492.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/664/prepub

doi:10.1186/1471-2407-10-664
Cite this article as: Jung et al. The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study. BMC Cancer 2010 10:664.